HomeComparePBIO vs EQR

PBIO vs EQR: Dividend Comparison 2026

PBIO yields 166666.67% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PBIO wins by $11911377672882.58M in total portfolio value
10 years
PBIO
PBIO
● Live price
166666.67%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$11911377672882.62M
Annual income
$5,393,136,696,480,418,000.00
Full PBIO calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — PBIO vs EQR

📍 PBIO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPBIOEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PBIO + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PBIO pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PBIO
Annual income on $10K today (after 15% tax)
$14,166,666.67/yr
After 10yr DRIP, annual income (after tax)
$4,584,166,192,008,355,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, PBIO beats the other by $4,584,166,192,008,352,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PBIO + EQR for your $10,000?

PBIO: 50%EQR: 50%
100% EQR50/50100% PBIO
Portfolio after 10yr
$5955688836441.33M
Annual income
$2,696,568,348,240,211,000.00/yr
Blended yield
45.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

PBIO
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-50.4
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PBIO buys
0
EQR buys
0
No recent congressional trades found for PBIO or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPBIOEQR
Forward yield166666.67%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%15.8%
Portfolio after 10y$11911377672882.62M$40.5K
Annual income after 10y$5,393,136,696,480,418,000.00$3,819.61
Total dividends collected$11310008644767.18M$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: PBIO vs EQR ($10,000, DRIP)

YearPBIO PortfolioPBIO Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$8,344,033$8,333,333.33$11,248$547.57+$8.33MPBIO
2$3,258,162,280$3,249,234,164.07$12,701$666.53+$3258.15MPBIO
3$596,362,299,915$592,876,066,275.31$14,405$814.59+$596362.29MPBIO
4$51,347,407,585,706$50,709,299,924,797.41$16,413$999.84+$51347407.57MPBIO
5$2,095,186,069,772,327$2,040,244,343,655,621.00$18,795$1,232.92+$2095186069.75MPBIO
6$41,143,898,865,343,200$38,902,049,770,686,810.00$21,639$1,527.95+$41143898865.32MPBIO
7$401,002,058,588,188,860$356,978,086,802,271,700.00$25,057$1,903.80+$401002058588.16MPBIO
8$2,054,879,028,737,436,700$1,625,806,826,048,074,500.00$29,197$2,385.87+$2054879028737.41MPBIO
9$6,091,813,996,637,570,000$3,893,093,435,888,512,500.00$34,250$3,008.70+$6091813996637.54MPBIO
10$11,911,377,672,882,618,000$5,393,136,696,480,418,000.00$40,467$3,819.61+$11911377672882.58MPBIO

PBIO vs EQR: Complete Analysis 2026

PBIOStock

Pressure BioSciences, Inc. develops and sells pressure-based platform solutions in the North America, Europe, and Asia. The company's pressure cycling technology (PCT) technology uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control the actions of molecules in biological samples, including cells and tissues from human, animal, plant, and microbial sources. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB880, Barocycler HUB440, and The Shredder SG3. The company also distributes cell disruption equipment, parts, and consumables. In addition, it offers Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, PCT-Micro Pestle, and pressure used to lyse samples for extraction tubes, as well as application specific kits, including consumable products and reagents. The company serves researchers at academic laboratories, government agencies, biotechnology companies, pharmaceutical firms, and other life science institutions. It has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; Steinbeis Centre for biopolymer analysis and biological mass spectrometry; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. Pressure BioSciences, Inc. was incorporated in 1978 and is based in South Easton, Massachusetts. As of August 2, 2022, Pressure BioSciences, Inc. operates as a subsidiary of Emergent Health Corp.

Full PBIO Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this PBIO vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PBIO vs SCHDPBIO vs JEPIPBIO vs OPBIO vs KOPBIO vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.